Raymond James Financial’s INmune Bio INMB Stock Holding History

Raymond James Financial’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$347K	Buy	212,995 +9,750	+5%	+$13.5K	﹤0.01%	4740
2026 Q1	$230K	Sell	203,245 -7,433	-4%	-$10.6K	﹤0.01%	4817
2025 Q4	$329K	Sell	210,678 -57,782	-22%	-$103K	﹤0.01%	4514
2025 Q3	$556K	Sell	268,460 -65,017	-19%	-$149K	﹤0.01%	4062
2025 Q2	$770K	Sell	333,477 -48,564	-13%	-$356K	﹤0.01%	3737
2025 Q1	$2.98M	Sell	382,041 -93,510	-20%	-$743K	﹤0.01%	2691
2024 Q4	$2.22M	Buy	+475,551	New	+$2.48M	﹤0.01%	2889

Other funds holding INMB

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Raymond James Financial's INMB Position: Q2 2026 in Review

Raymond James Financial increased its INmune Bio (INMB) stake by 4.8% in Q2 2026, buying an estimated $13.5K and bringing the position to 212,995 shares worth $347K. The position accounts for ﹤0.01% of the portfolio, ranked #4740.

Raymond James Financial first reported a position in INMB in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.98M in Q1 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

Raymond James Financial held 212,995 shares of INmune Bio worth $347K as of Q2 2026.
Raymond James Financial bought 9,750 INmune Bio shares in Q2 2026, an estimated $13.5K.
INmune Bio made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4740 holding.
Raymond James Financial first reported a position in INmune Bio in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's INmune Bio position peaked at $2.98M in Q1 2025.
82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.